NEW YORK (360Dx) – Oxford Immunotec reported Tuesday that its fourth quarter revenues increased 5 percent year over year, driven by continued growth in both its tuberculosis and tick-borne disease testing businesses.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.